Since taking over Accuray (NASDAQ:ARAY)
in October of 2012, Josh Levine has done a lot of good things at
Accuray. Not that you'd know it by the stock performance (down about 3%
over that stretch), but Levin has championed a reorganized sales force,
reduced operating costs, and significant improvements in product quality
and product development.
Unfortunately, there are still multiple
issues bedeviling Accuray. Communication with the Street, long an issue
of the prior management team, has emerged as an issue again as the
company has failed to adequately communicate the impact of order
age-outs to investors. There have also been challenges in getting the
CyberKnife multi-leaf collimator to market, not to mention the
challenges that go with competing against the 500lb gorilla that is Varian (NYSE:VAR).
Despite
these rather sizable bumps in the road, I'm still bullish on Accuray.
I've unfortunately gotten a much closer look at the realities of
radiation oncology and I continue to believe that Accuray's technology
and products can gain share in a changing radiation oncology market.
Continue reading here:
Ghosts Of Business Problems Past Visit Accuray Again
No comments:
Post a Comment